RBC Capital Markets | Healthcare Insights

Pathfinders Podcast | Healthcare

Few IPOs but plenty of follow-on for biotech in 2023

Biotech continues to bolster the healthcare market, but there are tailwinds for services and HCIT too, as well as a...

Pathfinders Podcast | Research

Biotech Halftime Report: A Winding Road Ahead

While competition and patent cliffs remain overhangs, innovation and regulatory permissiveness remain high, the macro...

6 min listen

Insights

Is the US Ready to Release the Therapeutic Potential of Psychedelics?

Society is poised to break through a long-standing wariness to harness the potential of controlled substances in the...

3 min watch

Insights

Finding Funds and Profits in a Tough Biotech Market

Nothing less than a cure for cancer is in the sights of immune medicine pioneer, Adaptive Biotechnologies. But first...

5 min watch

Insights

Countdown to the Biotech M&A Explosion

The biotech sector’s current lean financial spell is precisely the right time to invest, says industry leader, Dr Ted...

4 min watch

Insights

ESG Themes to Watch for in the Healthcare Sector

Sara Mahaffy, RBC’s ESG Strategist, provides a snapshot of key ESG themes, momentum, and proxy voting trends for the...

4 min read

Insights

What Changing ESG Sentiment May Mean for the Healthcare Sector

Prior to the RBC Capital Markets Global Healthcare Conference, Sara Mahaffy examined ESG momentum and how it impacts...

3 min read

Pathfinders in Biopharma Podcast

Stay ahead of the curve with the latest perspectives from the cutting edge of biotech and pharma.

Pathfinders Podcast | Investment Banking

ECM: Robust End to Year, Despite Previous Volatility

As RBC Capital Markets looks forward to a robust end to the year, John Hoffman and Jason Levitz, Co-Heads of Healthcare Equity...

4 min read

Latest Episodes

See all

Episode 17

When to Call it Quits: VCs Making Tough Decisions in a Tough Market

4 min read

Episode 19

Biotech M&A: Reshaping the Strategic Landscape

4 min read

Episode 16

The Power and Potential of Genetic Medicine

3 min read

Episode 15

The Hidden Revolution Set to Turn US Healthcare on its Head

3 min read

Episode 14

The Big Picture for Biotech

3 min read

Episode 13

Why Biopharma Investment Requires a Different Mindset

3 min read

Episode 12

The Optimism Behind the Biopharma Market

3 min read

Episode 11

Biotech Investors: How to Find Value in a Bear Market

5 min read

Episode 10

Serving the Underserved: Global Blood Therapeutics Commitment to Sickle-Cell Innovation

3 min read

Episode 9

Ionis: Raising the Bar for ESG

3 min read

Episode 8

Biotech and Big Pharma: Blueprint for Successful Partnership

5 min read

Episode 7

Inside Track: Behind the Scenes of a Major Biotech SPAC

4 min read

Episode 6

What’s Material in ESG for Biopharma Firms?

4 min read

Episode 5

Biotech SPACs: A New Route to Going Public

4 min read

Episode 4

5AM Ventures: Fueling the Next Generation of Innovators

3 min read

Episode 3

Vida Ventures: Powering Breakthroughs in Biopharma

3 min read

Episode 2

Biotech IPOs: Navigating the New Landscape

4 min read

Episode 1

Biotech IPOs: New Steps to Success on the Road to Going Public

3 min read

See All Episodes

More from RBC Capital Markets

Insights

Strategic Alternatives

Get the latest insights on issues impacting mergers and acquisitions from RBC Capital Markets’ investment banking team.

5 min watch

Insights

Markets in Motion Podcast

Our regular podcast from Lori Calvasina, Head of U.S. Equity Strategy, that brings a fresh perspective and nuanced, data driven view on the forces...

Learn More

Insights

RBC Imagine: The Future, in Focus

RBC Imagine pulls the future of business more clearly into focus. See the change drivers of tomorrow, sharpen your business thinking today.

20 min read

Recent Transactions

Undisclosed

Apax Partners agrees to sell Clinisupplies

Exclusive Financial Advisor / Pending

US $35.6 million

Societal CDMO’s $35.6 million follow-on offering

Sole Bookrunner

Undisclosed

IFM Investors acquires PRP Diagnostic Imaging

Exclusive Financial Advisor

US $575 million

Surgery Partners’ $575 million follow-on offering

Bookrunner

US $60 million

Marinus Pharmaceuticals $60 million follow-on offering

Joint Bookrunner

Undisclosed

SK Capital acquires Apotex

Lead Financial Advisor

More Transactions

Lead Today. Define Tomorrow.™

From insights and advisory services to excellence in execution, we are an innovative, trusted partner in capital markets, banking, and finance.

Investment Banking

Research

Global Markets

Healthcare Insights

Pathfinders in Biopharma Podcast

Featured Content

Few IPOs but plenty of follow-on for biotech in 2023

Biotech Halftime Report: A Winding Road Ahead

Is the US Ready to Release the Therapeutic Potential of Psychedelics?

Finding Funds and Profits in a Tough Biotech Market

Countdown to the Biotech M&A Explosion

ESG Themes to Watch for in the Healthcare Sector

What Changing ESG Sentiment May Mean for the Healthcare Sector

Changing How We Fight Childhood Cancer

The Power and Potential of Genetic Medicine

The Disruptive Forces Poised to Reshape Biotech

The Competitive Landscape of Gene Therapy and Immuno-oncology

Are we closer to a cure for sickle cell disease?

A pivotal year for PROTACs?

The Hidden Revolution Set to Turn US Healthcare on its Head

How is Healthcare Prepared as Pandemic Turns to Endemic?

Biotech Outlook 2023: Small is the New Big

Digital Health Hit by Macro Factors, but Fundamentals Remain Strong

The Big Picture for Biotech

Why Biopharma Investment Requires a Different Mindset

ESG Positioning and Sentiment Trends in the Healthcare Sector

Big Data in Medical Science

Innovation Powering Biotech, but Regulatory Concerns Ahead

The Optimism Behind the Biopharma Market

Reimagining the Future of Biotech

Biotech Halftime Report: After a Bumpy Year, is Biotech Ready to Bounce Back?

Pandemic Produced Lasting Changes in Medical Device Markets

Outlook for Healthcare Services, IT and Devices Remains Strong

“Large pharma has $500B it could deploy for M&A.”

Biotech Outlook 2022: Ample Opportunity for a Rebound

Digital Health Outlook 2022: Opportunities for the Discerning Investor

The Tech-Enabled Model Reshaping Healthcare

Brian Abrahams on what will shape the future of healthcare

The Pandemic Accelerates Healthcare Trends by a Decade

Gregory Renza on transformation shifts in biotech

Shagun Singh on new medical technologies

ESG Themes to Watch for in the Healthcare Sector

Medical Devices Industry Stabilizing, Set for New Growth Trajectory

Biotechs Race for Next-Gen Dystrophy and Ataxia Treatments

Biotech Investors: How to Find Value in a Bear Market

Building better healthcare through digitisation

How Genetic Medicine is Revolutionizing the Way We Treat Patients

How Biotech Breakthroughs are Changing Healthcare

Moderna co-founder Derrick Rossi on the new era for vaccines

Healthcare Experts See Near-term Hurdles, but Long-term Optimism in the Sector

Serving the Underserved: Global Blood Therapeutics Commitment to Sickle-Cell Innovation

Game Changers: Disruptive Forces in Biotech

Inside Track: Behind the Scenes of a Major Biotech SPAC

All eyes on gene/cell therapy and rare disease innovations

Genetic Medicine Leads a Surge of Innovation in Biotech

What’s Material in ESG for Biopharma Firms?

How the FDA’s Approval Of A New Alzheimer’s Drug Could Ripple Across the Biopharma Sector

#RBCHealthcare2021: Key Takeaways from our Global Healthcare Conference

The Vancouver biotech company on a mission to help the world

Why Alex Azar Still Believes in Value-Based Healthcare

Digital healthcare meets pandemic tipping point

Herd Immunity Update: Global Troubles, but Almost-Normal Arrives in U.S.

Virtual Health is the Future

Biotech’s Commitment to Sustainability and Innovation May Pave the Way for Achievement of ESG Goals

Biotech SPACs: A New Route to Going Public

Biotech Outlook 2021: Innovation, IPOs and COVID‑19

RBC Imagine: Game Changers for Biotech in 2021

Digital Health Outlook: Accelerated innovation and adoption continues in 2021

Key Healthcare Trends to Watch in 2021: Digital Health, Gene Therapy and Neurology

Sell a Little, Sell a Lot or Sell it All?

Key takeaways from our virtual global healthcare conference

Digital Therapeutics – embracing the next wave

Biotech and Big Pharma: Blueprint for Successful Partnership

New business models emerge

Healthcare Digitization

Amazon, CVS and Google: healthcare reimagined

The Rise of Telehealth

Vital Signs: Taking the Pulse of Healthcare M&A

The healthcare data explosion

Big tech vs big pharma: the tug of war has begun

How One Company Used AI to Detect the Coronavirus

5AM Ventures: Fueling the Next Generation of Innovators

Vida Ventures: Powering Breakthroughs in Biopharma